ArticleJournal of inflammation research2026
First-Line Guselkumab Combined with Exclusive Enteral Nutrition in Biologic-Naïve Young‑Onset Crohn's Disease: A Three-Case Series from China.
Article in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Guselkumab, a monoclonal antibody targeting the p19 subunit of interleukin‑23 (IL‑23), is a treatment option in inflammatory bowel disease (IBD). Evidence in young‑onset Crohn's disease (CD) in the first‑line setting remains scarce. Objective: To describe short-term clinical, biochemical, endoscopic and imaging outcomes with first-line guselkumab combined with exclusive enteral nutrition (EEN) in biologic-naïve young adults with CD. Methods: We report a case series of three biologic‑naïve young adults with moderate‑to‑severe CD confirmed by clinical, endoscopic, and imaging criteria. All received guselkumab combined with exclusive enteral nutrition as initial therapy and were followed for up to 20 weeks. Outcomes were assessed across clinical, endoscopic, and cross‑sectional imaging (intestinal ultrasound, computed tomography enterography, or magnetic resonance enterography) domains. Safety was monitored throughout. Results: All three patients achieved a clinical response and clinical remission by week 4. C‑reactive protein, fecal calprotectin, and bowel wall thickness decreased markedly after therapy. Computed tomography enterography and intestinal ultrasound suggested marked transmural improvement in all cases. Endoscopic assessment demonstrated endoscopic improvement or remission in all three patients. Diets were gradually liberalized in all patients. Guselkumab was generally well tolerated. Two patients exhibited mild, asymptomatic elevations of liver transaminases prior to the second or third dose, which were managed successfully with hepatoprotective therapy while continuing guselkumab. No serious adverse events occurred during follow‑up up to 20 weeks. Conclusion: In this three-case real-world series from China, first‑line guselkumab plus EEN was associated with rapid short-term improvement across clinical, biochemical, endoscopic and imaging domains and was generally well tolerated. These observations are preliminary and hypothesis-generating and require confirmation in larger prospective cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.